New Releases from NCBI BookshelfDurvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy.Durvalumab for treating limited-stage small-cell lung cancer after platinum-based chemoradiotherapy.
Post Content
Uncategorized
Uncategorized
New Releases from NCBI BookshelfSarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal).Sarilumab for treating polyarticular or oligoarticular juvenile idiopathic arthritis in people 2 to 17 years (terminated appraisal).
Post Content
Uncategorized
New Releases from NCBI BookshelfApplying Neurobiological Insights on Stress to Foster Resilience Across Life Stages: Proceedings of a Workshop.Applying Neurobiological Insights on Stress to Foster Resilience Across Life Stages: Proceedings of a Workshop.
Rising rates of stress, anxiety, and depression highlight the need to understand how the brain builds resilience across life stages.
Uncategorized
New Releases from NCBI BookshelfDual Therapy for Initial Treatment of Adult Patients With Pulmonary Arterial Hypertension: Health Technologies [Internet].Dual Therapy for Initial Treatment of Adult Patients With Pulmonary Arterial Hypertension: Health Technologies [Internet].
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by increases in pulmonary vascular resistance and pulmonary arterial pressure, which
Uncategorized
New Releases from NCBI BookshelfAcalabrutinib (Calquence): Indication: Acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant: Reimbursement Recommendation [Internet].Acalabrutinib (Calquence): Indication: Acalabrutinib in combination with bendamustine and rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma who are ineligible for autologous stem cell transplant: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Calquence should be reimbursed by public drug plans for the treatment of adult patients
Uncategorized
New Releases from NCBI BookshelfCabozantinib: Therapeutic area: Neuroendocrine tumours: Reimbursement Review [Internet].Cabozantinib: Therapeutic area: Neuroendocrine tumours: Reimbursement Review [Internet].
Neuroendocrine tumours (NETs), including extrapancreatic (epNET) and pancreatic (pNET) types, originate from secretory cells and can occur in various organs.
Uncategorized
New Releases from NCBI BookshelfBelantamab Mafodotin, Pomalidomide, Dexamethasone: Indication: Belantamab mafodotin is indicated, in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide: Reimbursement Recommendation [Internet].Belantamab Mafodotin, Pomalidomide, Dexamethasone: Indication: Belantamab mafodotin is indicated, in combination with pomalidomide and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide: Reimbursement Recommendation [Internet].
Canada’s Drug Agency (CDA-AMC) recommends that Blenrep in combination with pomalidomide and dexamethasone be reimbursed by public drug plans for
